Show simple item record

dc.contributor.authorYoung, Megan K
dc.contributor.authorBertolini, Joseph
dc.contributor.authorKotharu, Pushpa
dc.contributor.authorMaher, Darryl
dc.contributor.authorCripps, Allan W
dc.date.accessioned2018-01-22T01:16:20Z
dc.date.available2018-01-22T01:16:20Z
dc.date.issued2017
dc.identifier.issn2164-5515
dc.identifier.doi10.1080/21645515.2016.1234554
dc.identifier.urihttp://hdl.handle.net/10072/143163
dc.description.abstractThe effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titer of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2). Measles titres in Australian IM and IV immunoglobulins ranged from 51 to 76 IU/mL and 6 to 24 IU/mL respectively, as measured by PRNT calibrated to the WHO 3rd international standard. ELISA titres were variable but higher than PRNT titres in all tested samples. Measles antibody titres in Australian immunoglobulin products meet consensus-prescribed international thresholds. Development of a convenient, standardized, readily accessible assay for determination of measles titres in immunoglobulin products would be useful for future studies and facilitate international comparisons.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto18
dc.relation.ispartofjournalHuman Vaccines & Immunotherapeutics
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchImmunology not elsewhere classified
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3204
dc.subject.fieldofresearchcode320499
dc.subject.fieldofresearchcode3207
dc.subject.fieldofresearchcode3214
dc.titleDo Australian immunoglobulin products meet international measles antibody titre standards?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.
gro.hasfulltextNo Full Text
gro.griffith.authorCripps, Allan W.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record